While one pilot study investigating 8 weeks of oxytocin vs. placebo in humans with obesity showed promising results with significant BMI reduction (3.2 ± 1.9 kg/m2) [235], research is currently ongoing to investigate the efficacy and safety of chronic IN oxytocin administration as a weight-loss therapeutic in adults and adolescents (ClinicalTrials.gov Identifiers: NCT03043053 and NCT04551482, respectively). The gene discussed is OXT; the disease is obesity due to melanocortin 4 receptor deficiency.